Bruker BioSciences Corporation to Present at Lehman Brothers Ninth Annual Global Healthcare Conference; Live Webcast on Friday,

Bruker BioSciences Corporation (Nasdaq: BRKR) today
announced that it will join other leading life sciences companies in
presenting at the Lehman Brothers Ninth Annual Global Healthcare
Conference now taking place March 8 through 10 in Miami. Bruker
BioSciences Corporation's President and CEO, Frank H. Laukien, will
present an overview of the Company, including an update on recent
developments, recently-announced product innovations, and
expectations.
   Dr. Laukien's presentation will be webcast live at 10:45 AM
Eastern Time (7:45 AM Pacific Time) on Friday, March 10, 2006 from the
Loews Miami Beach Hotel. The webcast can be accessed on Bruker
BioSciences' website at www.bruker-biosciences.com with playback.

   ABOUT BRUKER BIOSCIENCES

   Bruker BioSciences Corporation, headquartered in Billerica,
Massachusetts, is the publicly traded parent company of Bruker AXS
Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and
provider of life science, materials research and industrial X-ray
analysis tools. Bruker Daltonics is a leading developer and provider
of innovative life science tools based on mass spectrometry. For more
information, please visit www.bruker-biosciences.com.

   CAUTIONARY STATEMENT

   Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements as
that term is defined in the Private Securities Litigation Reform Act
of 1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of conditions,
technological approaches, product development, market acceptance, cost
and pricing of the Company's products, changes in governmental
regulations, capital spending and government funding policies, FDA and
other regulatory approvals to the extent applicable, competition, the
intellectual property of others, patent protection and litigation.
These and other factors are identified and described in more detail in
our filings with the SEC, including, without limitation, our annual
report on Form 10-K, our most recent quarterly reports on Form 10-Q
and our current reports on Form 8-K. We disclaim any intent or
obligation to update these forward-looking statements.